Shopping Cart
- Remove All
- Your shopping cart is currently empty
Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $78 | In Stock | |
5 mg | $237 | In Stock | |
10 mg | $383 | In Stock | |
25 mg | $629 | In Stock | |
50 mg | $889 | In Stock |
Description | Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells. |
Targets&IC50 | LUAD-0061AS3 cell:1.4 μM, MCF-7 cell:45.2 μM, MDA-MB-175-VII cell:0.02 μM, HBECp53 cell:203 μM |
In vitro | Methods: seribantumab (0.1, 1, 10 μM) was used to treat cancer cells. Results: seribantumab inhibited neuregulin (NRG1) fusion dependent tumorigenosis. The IC50 values of Seribantumab for MDA-MB-175-VII cells, LUAD-0061AS3 cells, MCF-7 cells, and HBECp53 cells were 0.02 μM, 1.4 μM, 45.2 μM, and 203 μM, respectively. [1] |
In vivo | Seribantumab (0.6 mg, 0.75 mg, or 1 mg per dose twice weekly) was injected into mice with LUAD-0061AS3 PDX tumors, and results showed that seribantumab was more effective than afatinib in reducing tumor growth. [1] |
Alias | SAR-256212, SAR256212, MM-121, MM121 |
Molecular Weight | 143.2 (kDa) |
Cas No. | 1334296-12-6 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.